drugset / Trial / NCT01556646
Effect of Tolvaptan on Cognitive Function in Cirrhosis
Phase 3
Completed
25 enrolled
Hunter Holmes Mcguire Veteran Affairs Medical Center
Otsuka America Pharmaceutical · collab
NaSingle-groupOpen-labelTreatment
Summary
Hypothesis: Tolvaptan will improve cognitive function, brain edema and health-related quality of life in cirrhotic patients with hyponatremia
Timeline
- Start
- 2011-04
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tolvaptan | Unknown | 15 mg | — |
| Subject | Tolvaptan | Unknown | 30 mg | — |